Fulphila Injection 6 mg/0.6 ml contains Pegfilgrastim, a long-acting pegylated form of filgrastim, which is a recombinant human granulocyte colony-stimulating factor (G-CSF). It is used to reduce the risk of infection in patients receiving myelosuppressive chemotherapy by stimulating the production of neutrophils. Fulphila Injection plays a vital role in supportive cancer care by helping maintain adequate white blood cell counts and minimizing chemotherapy-related complications.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Active Ingredient: Pegfilgrastim 6 mg per 0.6 ml

• Dosage Form: Sterile solution for injection (subcutaneous use)

Therapeutic Class

• Hematopoietic Growth Factor

• Granulocyte Colony-Stimulating Factor (G-CSF)

Indications

Fulphila Injection 6 mg/0.6 ml is indicated for:

• Reduction of the duration and incidence of chemotherapy-induced neutropenia

• Decreasing the risk of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy

• Supportive care in oncology patients to reduce infection-related complications

It is not indicated for use in patients receiving chemotherapy for myeloid malignancies.

Pharmacology

Pegfilgrastim works by binding to specific receptors on hematopoietic cells in the bone marrow, stimulating the proliferation, differentiation, and activation of neutrophil precursors. Pegylation significantly prolongs its half-life by reducing renal clearance, allowing sustained activity with a single dose per chemotherapy cycle. This extended duration of action enables effective neutrophil recovery and reduces the need for daily injections associated with non-pegylated filgrastim.

Dosage and Administration

The recommended dose of Fulphila Injection is:

• One subcutaneous injection of 6 mg once per chemotherapy cycle

It should be administered at least 24 hours after completion of cytotoxic chemotherapy and not within 14 days before the next chemotherapy dose. Administration should be carried out under the supervision of a healthcare professional, and proper injection technique must be followed.

Contraindications

Fulphila Injection is contraindicated in patients with:

• Known hypersensitivity to pegfilgrastim, filgrastim, or any component of the formulation

• History of serious allergic reactions to G-CSF products

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Use with caution in patients with sickle cell disorders, as severe crises have been reported

• Splenic enlargement or rupture may occur; patients should report left upper abdominal or shoulder pain

• Monitor for signs of acute respiratory distress syndrome and allergic reactions

• Leukocytosis may occur and should be monitored during treatment

Use in Special Populations

• Pregnancy: Use only if clearly needed and prescribed by a physician

• Lactation: Use with caution under medical supervision

• Pediatric Use: Safety and efficacy should be determined by a specialist

Storage Conditions

• Store at 2°C to 8°C in a refrigerator

• Do not freeze

• Protect from light

• Keep out of reach of children

Presentation

Fulphila Injection 6 mg/0.6 ml is supplied as a prefilled syringe, designed for accurate dosing, ease of administration, and enhanced patient safety in clinical practice.